Panacea Biotec brings unique Indian CB

Pharma company brings unusual structured CB.

Panacea Biotec, one of IndiaƆs top-three pharmaceutical companies, has sold $100 million worth of highly-structured convertible bonds through Merrill Lynch to raise cash for its future expansion in India and offshore.

The five-year bonds, which were split into two equal-sized tranches, have two unusual features, which together make this a unique deal in the Indian market. Most notably, the conversion price will be fixed only six months from the issue date and there is also a mandatory conversion feature after...

To continue reading, please login or register for free

Click for more on: cb | pharmaceutical | biotechnology

Print Edition

FinanceAsia Print Edition


  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...